Cytosorbents Corp

Cytosorbents operates with a market capitalization of $33.97 million and a price-to-book ratio of 1.79, indicating a premium to its book value. The company holds $8.61 million in cash and equivalents, while its total liabilities amount to $28.14 million, resulting in a debt-to-equity ratio of 0.23 and a current ratio of 1.49, suggesting moderate liquidity. Despite this, the company reported negative operating and free cash flows of -$4.83 million and -$5.82 million, respectively, highlighting cash flow constraints. Profitability metrics show a return on equity of -32.17% and a return on assets of -12.94%, both significantly below industry norms for medical equipment firms. Gross profit of $6.87 million on $8.99 million in revenue indicates a gross margin of 76.4%, which is strong but insufficient to offset operating expenses, resulting in a net loss of $6.09 million. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, raising concerns about exposure to market-specific risks. No material revenue concentration by geography is reported, but the lack of segmental or geographic breakdown limits visibility into operational diversification. Looking ahead, the company is projected to maintain a negative growth trajectory, with no disclosed revenue growth in the current fiscal year and no forward-looking guidance provided. The absence of capital expenditure growth and the continued operating losses suggest a lack of investment in future capacity or innovation. Risk factors include low liquidity and the potential for dilution, though no immediate filing-based flags were detected. The company's negative cash flows and operating losses increase the risk of future dilutive financing, particularly if cash reserves fall below operational needs. No recent material events, such as significant filings or earnings transcripts, were identified in the available data.